GlobalData on MSN15h
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trialAnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...
This article helps to dispel myths related to rheumatoid arthritis (RA) and raise awareness regarding it. From causes to ...
Investor's Business Daily on MSN18h
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis TreatmentAnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback